HK1221766A1 - 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 - Google Patents

通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 Download PDF

Info

Publication number
HK1221766A1
HK1221766A1 HK16109795.0A HK16109795A HK1221766A1 HK 1221766 A1 HK1221766 A1 HK 1221766A1 HK 16109795 A HK16109795 A HK 16109795A HK 1221766 A1 HK1221766 A1 HK 1221766A1
Authority
HK
Hong Kong
Prior art keywords
antibiotic
disease
pct
heart failure
use according
Prior art date
Application number
HK16109795.0A
Other languages
English (en)
Chinese (zh)
Inventor
Bergmann Andreas
Struck Joachim
Original Assignee
B.R.A.H.M.S Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40886944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1221766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by B.R.A.H.M.S Gmbh filed Critical B.R.A.H.M.S Gmbh
Publication of HK1221766A1 publication Critical patent/HK1221766A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16109795.0A 2009-04-14 2016-08-16 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估 HK1221766A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157886.4 2009-04-14
EP09157886 2009-04-14

Publications (1)

Publication Number Publication Date
HK1221766A1 true HK1221766A1 (zh) 2017-06-09

Family

ID=40886944

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109795.0A HK1221766A1 (zh) 2009-04-14 2016-08-16 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估

Country Status (15)

Country Link
US (3) US9046532B2 (https=)
EP (1) EP2419741B1 (https=)
JP (1) JP5650718B2 (https=)
CN (2) CN105334330A (https=)
CY (1) CY1122202T1 (https=)
DK (1) DK2419741T3 (https=)
ES (1) ES2751105T3 (https=)
HK (1) HK1221766A1 (https=)
HR (1) HRP20191862T1 (https=)
HU (1) HUE046182T2 (https=)
LT (1) LT2419741T (https=)
PL (1) PL2419741T3 (https=)
PT (1) PT2419741T (https=)
SI (1) SI2419741T1 (https=)
WO (1) WO2010118855A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
CN105528511A (zh) * 2014-10-25 2016-04-27 潘一琦 一种远程诊疗对比式问诊方法及其系统
CN107301319B (zh) * 2017-06-26 2021-02-26 济南市儿童医院 儿科临床及科研中抗菌药物使用危险评估系统
JP7444776B2 (ja) * 2017-12-20 2024-03-06 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
ATE395364T1 (de) * 1999-12-22 2008-05-15 Dade Behring Marburg Gmbh Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
FR2894675B1 (fr) * 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
CN103123359B (zh) * 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用

Also Published As

Publication number Publication date
WO2010118855A1 (en) 2010-10-21
HRP20191862T1 (hr) 2019-12-27
EP2419741A1 (en) 2012-02-22
HUE046182T2 (hu) 2020-02-28
CN102395888B (zh) 2017-05-03
PL2419741T3 (pl) 2020-01-31
JP2012523573A (ja) 2012-10-04
CY1122202T1 (el) 2020-11-25
LT2419741T (lt) 2019-11-11
EP2419741B1 (en) 2019-07-31
US9810699B2 (en) 2017-11-07
DK2419741T3 (da) 2019-11-04
JP5650718B2 (ja) 2015-01-07
US20180052179A1 (en) 2018-02-22
US20120100635A1 (en) 2012-04-26
US20150247871A1 (en) 2015-09-03
ES2751105T3 (es) 2020-03-30
US9046532B2 (en) 2015-06-02
SI2419741T1 (sl) 2019-12-31
PT2419741T (pt) 2019-11-04
CN105334330A (zh) 2016-02-17
CN102395888A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
CN102105794B (zh) 移植物衰竭和死亡的标志物
CN102317790B (zh) Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
RU2672561C2 (ru) Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
EP2353011B1 (en) Biomarker for the prediction of first adverse events
US11835531B2 (en) Procalcitonin for the prognosis of adverse events
CN101194167A (zh) NT-proANP和NT-proBNP用于诊断心脏病的用途
JP4838794B2 (ja) 心臓毒性医薬の結果として心血管合併症に罹患するリスクを診断するための心臓ホルモンの使用
HK1221766A1 (zh) 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估
JP7540074B2 (ja) Ｃｏｖｉｄ－１９患者の疾患重症度を予測するためのｇｄｆ－１５
JP2023537749A (ja) 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７
HK1167181B (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
HK1167181A (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
CN110646626B (zh) 24-羟基胆固醇在制备诊断或早期诊断精神分裂症的产品中的用途
HK1169165B (en) Procalcitonin for the prognosis of adverse events
HK1203611B (en) Prognosis of adverse events in patients with suspected chronic heart failure
HK1121527A (en) Use of nt-proanp and nt-probnp for diagnosing cardiac diseases
HK1164999A (en) Biomarker for the prediction of first adverse events